Results 71 to 80 of about 52,496 (299)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study [PDF]

, 2018
Background: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive ...
Birk, Ruby, Brealey, Noushin, Bremner, Peter R, Ismaila, Afisi S, Lipson, David A, Zhu, Chang-Qing   +5 more
core   +2 more sources

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Alpha9 nicotinic acetylcholine receptors and the treatment of pain [PDF]

, 2009
Chronic pain is a vexing worldwide problem that causes substantial disability and consumes significant medical resources. Although there are numerous analgesic medications, these work through a small set of molecular mechanisms.
Absalom, Nathan, Chebib, Mary, Elgoyhen, Ana Belen, McIntosh, J. Michael, Vincler, Michelle   +4 more
core   +1 more source

Beta‐blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes

European Journal of Heart Failure, EarlyView.
In total, 5084 patients from Swedish registries with both heart failure (HF) with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) were included. Confounding was handled by overlap weighting based on propensity scores for beta‐blocker use. Patients were followed up for 5 years, or until death, emigration from Sweden or
Benedikt N. Beer, Lina Benson, Christian Basile, Benedikt Schrage, Peter Moritz Becher, Stefan Blankenberg, Paulus Kirchhof, Barna Szabó‐Söderberg, Marco Metra, Anne Lindberg, Egidio Imbalzano, Giuseppe M. C. Rosano, Patric Karlström, Peter G.M. Mol, Raffaele Scorza, Lars H. Lund, Felix Lindberg, Gianluigi Savarese   +17 more
wiley   +1 more source

Simultaneous release of glutamate and acetylcholine from single magnocellular "cholinergic" basal forebrain neurons [PDF]

, 2006
Basal forebrain (BF) neurons provide the principal cholinergic drive to the hippocampus and cortex. Their degeneration is associated with the cognitive defects of Alzheimer's disease. Immunohistochemical studies suggest that some of these neurons contain
Abogadie, FC, Allen, TGJ, Brown, DA
core   +1 more source

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Main categories of harmful drugs in heart failure. CCB, calcium channel blocker; DPP4i, dipeptidyl peptidase‐4 inhibitor; HER2‐TT, human epidermal growth factor receptor 2‐targeted therapy; NSAID, non‐steroidal anti‐inflammatory drug; TKI, tyrosine kinase inhibitor; TZD, thiazolidinedione; VEGF Inh, vascular endothelial growth factor inhibitor.
Amr Abdin, Johann Bauersachs, Magdy Abdelhamid, Suleman Aktaa, Hussam Al Ghorani, Antonio Bayes‐Genis, Jan Biegus, Michael Böhm, Javed Butler, Nicolas Girerd, Marco Metra, Wilfried Mullens, Hadi Skouri, Muthiah Vaduganathan, Seif El Hadidi, Giuseppe M.C. Rosano, Gianluigi Savarese   +16 more
wiley   +1 more source

The possible mechanisms of protocatechuic acid-induced central analgesia

Saudi Pharmaceutical Journal, 2018
It is aimed to investigate the central antinociceptive effect of protocatechuic acid and the involvement of stimulation of opioidergic, serotonin 5-HT2A/2C, α2-adrenergic and muscarinic receptors in protocatechuic acid-induced central analgesia in mice ...
Rana Arslan, Sule Aydin, Dilara Nemutlu Samur, Nurcan Bektas   +3 more
doaj   +1 more source

Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors. [PDF]

PLoS ONE, 2014
Xanomeline is an agonist endowed with functional preference for M1/M4 muscarinic acetylcholine receptors. It also exhibits both reversible and wash-resistant binding to and activation of these receptors.
Eva Šantrůčková, Vladimír Doležal, Esam E El-Fakahany, Jan Jakubík   +3 more
doaj   +1 more source

Presynaptic M1 muscarinic cholinoceptors mediate inhibition of excitatory synaptic transmission in the hippocampus in vitro [PDF]

, 1990
The effects of the cholinoceptor agonist, carbachol (CCh), were examined in the rat hippocampal slice preparation. Intracellular recordings from CA1 pyramidal neurones revealed that CCh (1–3 μM) inhibited excitatory postsynaptic responses evoked by ...
Sheridan, Robert D., Sutor, Bernd
core   +1 more source

Status epilepticus: Updates on mechanisms and treatments

Epilepsia Open, EarlyView.
Abstract Status epilepticus (SE) consists of prolonged, self‐sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super‐refractory SE.
Suchitra Joshi, Jaideep Kapur
wiley   +1 more source